QUESHA FOSTER: Open Payments
NPI 1528631066 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,312 in 56 payments from 13 companies in 2025. Trend: 2023 $260 · 2024 $451 · 2025 $1,312
Food & beverage: $1,312
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $237 |
| Celltrion USA Inc. | 7 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $184 |
| Gilead Sciences, Inc. | 1 | $120 |
| Madrigal Pharmaceuticals | 5 | $98 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $96 |
| Janssen Biotech, Inc. | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $63 |
| Novo Nordisk Inc | 2 | $51 |
Products named: VEGZELMA, ENTYVIO, Livdelzi, REZDIFFRA, RINVOQ, XIFAXAN, CREON, TREMFYA.
Industry payments across GA — which companies pay providers there.
